{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:32:49Z","timestamp":1784064769193,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40620-020-00781-6","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T15:02:36Z","timestamp":1593270156000},"page":"565-571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli\u2019s regimen in membranous nephropathy"],"prefix":"10.1093","volume":"34","author":[{"given":"Roberta","family":"Fenoglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Baldovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Quattrocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Naretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,27]]},"reference":[{"issue":"3","key":"781_CR1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2215\/CJN.04321007","volume":"3","author":"FC Fervenza","year":"2008","unstructured":"Fervenza FC, Sethi S, Specks U (2008) Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 3(3):905\u2013919","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 1","key":"781_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000481635","volume":"47","author":"AS Bomback","year":"2018","unstructured":"Bomback AS, Fervenza FC (2018) Membranous nephropathy: approaches to treatment. Am J Nephrol 47(Suppl 1):30\u201342. https:\/\/doi.org\/10.1159\/000481635","journal-title":"Am J Nephrol"},{"issue":"1","key":"781_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/ndt\/gfr285","volume":"27","author":"N Polanco","year":"2012","unstructured":"Polanco N, Guti\u00e9rrez E, Rivera F, Castellanos I, Baltar J, Lorenzo D, Praga M, Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Espa\u00f1ola de Nefrolog\u00eda (GLOSEN) (2012) Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. Nephrol Dial Transplant 27(1):231\u2013234. https:\/\/doi.org\/10.1093\/ndt\/gfr285","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"781_CR4","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/ndt\/gfv435","volume":"31","author":"DA Kanigicherla","year":"2016","unstructured":"Kanigicherla DA, Short CD, Roberts SA, Hamilton P, Nikam M, Harris S, Brenchley PE, Venning MC (2016) Long-term outcomes of persistent disease and relapse in primary membranous nephropathy. Nephrol Dial Transplant 31(12):2108\u20132114. https:\/\/doi.org\/10.1093\/ndt\/gfv435","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"781_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"S Troyanov","year":"2004","unstructured":"Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry Group (2004) Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 66(3):1199\u20131205. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00873.x","journal-title":"Kidney Int"},{"key":"781_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"K Disease","year":"2012","unstructured":"Disease K (2012) Improving global outcomes (KDIGO): KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:139\u2013274","journal-title":"Kidney Int Suppl"},{"issue":"9868","key":"781_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","volume":"381","author":"A Howman","year":"2013","unstructured":"Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, Jayne DR, O'Donoghue D, Boulton-Jones M, Mathieson PW (2013) Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381(9868):744\u2013751. https:\/\/doi.org\/10.1016\/S0140-6736(12)61566-9","journal-title":"Lancet"},{"key":"781_CR8","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2215\/CJN.05231008","volume":"4","author":"AS Bomback","year":"2009","unstructured":"Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH (2009) Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 4:734\u2013744. https:\/\/doi.org\/10.2215\/CJN.05231008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9337","key":"781_CR9","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","volume":"360","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi G, Chiurchiu C, Abbate M et al (2002) Rituximab for idiopathic membranous nephropathy. Lancet 360(9337):923\u2013924 (Erratum in: Lancet 2002 Dec 21-28;360(9350):2090. https\/\/doi.org\/10.1016\/S0140-6736(02)11042-7)","journal-title":"Lancet"},{"issue":"1","key":"781_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.24920\/21803","volume":"33","author":"P Xu","year":"2018","unstructured":"Xu P, He YD, Yu ZM, Luo K, Xie HY, Zou PM, Gu X, Wang SR, Cai JF, Xu Q, Li H, Li XW (2018) Therapy of rituximab in idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis. Chin Med Sci J 33(1):9\u201319. https:\/\/doi.org\/10.24920\/21803","journal-title":"Chin Med Sci J"},{"issue":"6","key":"781_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.autrev.2016.02.014","volume":"15","author":"D Roccatello","year":"2016","unstructured":"Roccatello D, Sciascia S, Di Simone D, Solfietti L, Naretto C, Fenoglio R, Baldovino S, Menegatti E (2016) New insights into immune mechanisms underlying response to rituximab in patients with membranous nephropathy: a prospective study and a review of the literature. Autoimmun Rev 15(6):529\u2013538. https:\/\/doi.org\/10.1016\/j.autrev.2016.02.014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"781_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.kint.2017.01.01","volume":"92","author":"M Rosenzwajg","year":"2017","unstructured":"Rosenzwajg M, Languille E, Debiec H, Hygino J, Dahan K, Simon T, Klatzmann D, Ronco P et al (2017) Kidney Int 92(1):227\u2013237. https:\/\/doi.org\/10.1016\/j.kint.2017.01.01","journal-title":"Kidney Int"},{"issue":"1","key":"781_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, MENTOR Investigators et al (2019) Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381(1):36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1814427(Treatment of idiopathic membranous nephropathy (MENTOR). Nephron 130(3):159\u2013168)","journal-title":"N Engl J Med"},{"issue":"5","key":"781_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/ckj\/sfv075","volume":"8","author":"J Rojas-Rivera","year":"2015","unstructured":"Rojas-Rivera J, Fern\u00e1ndez-Ju\u00e1rez G, Ortiz A, Hofstra J, Gesualdo L, Tesar V, Wetzels J, Segarra A, Egido J, Praga M (2015) A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with tacrolimus-rituximab versus steroids plus cyclophosphamide in patients with primary membranous nephropathy: the STARMEN study. Clin Kidney J 8(5):503\u2013510. https:\/\/doi.org\/10.1093\/ckj\/sfv075","journal-title":"Clin Kidney J"},{"issue":"5","key":"781_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2215\/CJN.01180307","volume":"2","author":"P Cravedi","year":"2007","unstructured":"Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G (2007) Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2(5):93","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"781_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpneph1007","volume":"5","author":"P Ruggenenti","year":"2009","unstructured":"Ruggenenti P, Cravedi P, Remuzzi G (2009) Rituximab for membranous nephropathy and immune disease: less might be enough. Nat Clin Pract Nephrol 5(2):76\u201377","journal-title":"Nat Clin Pract Nephrol"},{"issue":"3","key":"781_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ckj\/sfx105","volume":"11","author":"S Bagchi","year":"2018","unstructured":"Bagchi S, Subbiah AK, Bhowmik D, Mahajan S, Yadav RK, Kalaivani M, Singh G, Dinda A, Kumar Agarwal S (2018) Low-dose rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience. Clin Kidney J 11(3):337\u2013341. https:\/\/doi.org\/10.1093\/ckj\/sfx105","journal-title":"Clin Kidney J"},{"issue":"10","key":"781_CR18","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/ndt\/gfw251","volume":"32","author":"G Moroni","year":"2017","unstructured":"Moroni G, Depetri F, Del Vecchio L, Gallelli B, Raffiotta F, Giglio E, Brunini F, D'Amico M, Longhi S, Radice A, Messa P, Sinico RA (2017) Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant 32(10):1691\u20131696. https:\/\/doi.org\/10.1093\/ndt\/gfw251","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"781_CR19","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.11791018","volume":"4","author":"B Seitz-Polski","year":"2009","unstructured":"Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, Ticchioni M, Rosenthal A, Benzaken S, Bernard G, Lambeau G, Ronco P, Esnault VLM (2009) High-dose rituximab and early remission in pla2r1-related membranous nephropathy. Clin J Am Soc Nephrol 4(8):1173\u20131182. https:\/\/doi.org\/10.2215\/CJN.11791018","journal-title":"Clin J Am Soc Nephrol"},{"key":"781_CR20","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1002\/sim.3854","volume":"29","author":"PC Austin","year":"2010","unstructured":"Austin PC (2010) The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med 29:2137\u20132148","journal-title":"Stat Med"},{"key":"781_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/sim.4780080504","volume":"8","author":"S Durrleman","year":"1989","unstructured":"Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551\u2013561","journal-title":"Stat Med"},{"key":"781_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150\u2013161","journal-title":"Pharm Stat"},{"key":"781_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri215529","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715\u2013725. https:\/\/doi.org\/10.1038\/nri215529","journal-title":"Nat Rev Immunol"},{"key":"781_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","volume":"3","author":"TT Kuo","year":"2011","unstructured":"Kuo TT, Aveson VG (2011) Neonatal Fc receptor and IgG-based therapeutics. MAbs 3:422\u2013430. https:\/\/doi.org\/10.4161\/mabs.3.5.16983","journal-title":"MAbs"},{"key":"781_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4161\/mabs.4.1.18543","volume":"4","author":"R Deng","year":"2012","unstructured":"Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, Prabhu S (2012) Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs 4:101\u2013109. https:\/\/doi.org\/10.4161\/mabs.4.1.18543","journal-title":"MAbs"},{"issue":"12","key":"781_CR26","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","volume":"5","author":"P Hamilton","year":"2010","unstructured":"Hamilton P, Kanigicherla D, Venning M, Brenchley P, Meads D (2010) Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 5(12):2188\u20132198. https:\/\/doi.org\/10.2215\/CJN.05080610","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"781_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, J\u00fcni P, Cattran DC, MENTOR Investigators (2019) Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381(1):36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1814427","journal-title":"N Engl J Med"},{"issue":"1","key":"781_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P, GEMRITUX Study Group (2017) Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. Am Soc Nephrol J 28(1):348\u2013358. https:\/\/doi.org\/10.1681\/ASN.2016040449","journal-title":"Am Soc Nephrol J"},{"issue":"12","key":"781_CR29","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/ndt\/gfy049","volume":"33","author":"P Hamilton","year":"2018","unstructured":"Hamilton P, Kanigicherla D, Venning M, Brenchley P, Meads D (2018) Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a health economic model. Nephrol Dial Transplant 33(12):2145\u20132155. https:\/\/doi.org\/10.1093\/ndt\/gfy049","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-020-00781-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:25Z","timestamp":1777564465000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/34\/2\/565\/8325610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,27]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1007\/s40620-020-00781-6","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,27]]},"assertion":[{"value":"5 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declares that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted retrospectively from data obtained for clinical purposes and it did not need ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}